The FDA has approved WGc-043, marking a historic milestone as the first mRNA vaccine developed for treating Epstein-Barr virus-related cancers. This groundbreaking development represents a significant advancement in oncology treatment, offering new therapeutic options for patients with advanced EBV-related malignancies.
WestGene's WGc-043, an mRNA therapeutic cancer vaccine, has received IND approvals from both China's NMPA and the US FDA, marking a global first for EBV-related cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.